Natural History of Merkel Cell Carcinoma Following Locoregional Recurrence
Overview
Affiliations
Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with an ill-defined natural history following locoregional recurrence.
Methods: This is a retrospective review of patients with MCC diagnosed at the Mayo Clinic from 1981 to 2008. For each outcome (subsequent locoregional recurrence, distant recurrence, and death) the survival-free of the outcome was estimated using the Kaplan-Meier method. Associations of patient and clinical characteristics with the outcomes were assessed by fitting Cox proportional hazards regression models.
Results: Among the 240 patients diagnosed with MCC, 70 (29%) patients were identified who developed locoregional recurrence as the first site of recurrence. The median time from diagnosis to locoregional recurrence was 6 months. The pattern of first locoregional failure in this group includes 25 (10.4%) local, 18 (7.5%) in-transit, and 27 (11.3%) nodal recurrences. Recurrences were most commonly treated by surgery and radiation. At 3 years after the initial recurrence, locoregional recurrence-free survival was 75% and the distant recurrence-free survival was 56%. Locoregional recurrence is a poor prognostic sign associated with a 3-year overall survival of 39%. Nodal status at time of original surgery and time to first recurrence were important predictors of distant recurrence (P < 0.006) and overall survival following locoregional recurrence (P < 0.001).
Conclusions: Locoregional recurrence is a substantial problem in patients with MCC and is a poor prognostic sign. In those patients who experience a locoregional recurrence, aggressive efforts to regain locoregional control appear warranted and may result in long-term survival.
Lugowska I, Becker J, Ascierto P, Veness M, Blom A, Lebbe C ESMO Open. 2024; 9(5):102977.
PMID: 38796285 PMC: 11145756. DOI: 10.1016/j.esmoop.2024.102977.
Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.
Zaggana E, Konstantinou M, Krasagakis G, de Bree E, Kalpakis K, Mavroudis D Cancers (Basel). 2023; 15(1).
PMID: 36612102 PMC: 9817518. DOI: 10.3390/cancers15010103.
Mahajan S, Barker C, Mauguen A, DAngelo S, Yeh R, Pandit-Taskar N J Nucl Med. 2021; 63(6):906-911.
PMID: 34620729 PMC: 9157731. DOI: 10.2967/jnumed.121.262882.
Cook M, Baker K, Redman M, Lachance K, Nguyen M, Parvathaneni U Am J Clin Oncol. 2018; 42(1):82-88.
PMID: 30211723 PMC: 8666386. DOI: 10.1097/COC.0000000000000482.
Tseng Y, Nguyen M, Baker K, Cook M, Redman M, Lachance K Int J Radiat Oncol Biol Phys. 2018; 102(2):330-339.
PMID: 30191867 PMC: 9592535. DOI: 10.1016/j.ijrobp.2018.05.075.